Idenix, Novartis hepatitis drug meets trial goal

Idenix Pharmaceuticals and Swiss drug maker Novartis said telbivudine, their experimental drug for hepatitis B, met its primary goal in a Phase III trial. The 1,350-patient study showed telbivudine was at least as effective as lamivudine, the standard Hepatitis B treatment, after one year of use. The companies said they plan to ask US regulators for approval by the end of 2005.

- read this press release for more

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.